News | March 01, 2023
NATCO launches generic Pomalidomide Capsules in Canada
Natco launched pomalidomide under their brand NAT-POMALIDOMIDE in strengths of 1 mg, 2 mg, 3 mg and 4 mg capsules
Natco launched pomalidomide under their brand NAT-POMALIDOMIDE in strengths of 1 mg, 2 mg, 3 mg and 4 mg capsules
Amala Hospital partners with LifeSigns to provide revolutionary technology for the first time in the State
Receives Subject Expert Committee recommendation to bring new therapies of Pompe, ASMD to India
Twelve hospitals across India will be part of the network which will support the trial in India
First approval for Daiichi Sankyo and AstraZeneca’s ENHERTU in China
New workflow integrates the xCELLigence RTCA HT with the BioTek BioSpa 8 Automated Incubator
The British-Swedish pharma major certainly has a strong competitive edge for BTC treatment in the country
Merck and Ridgeback will appeal the decision and request a re-examination of the CHMP’s opinion.
This sBLA submission is supported by clinical, pre-clinical, and manufacturing data demonstrating the safety, tolerability, and immunogenicity of the bivalent vaccine.
Submissions based on favorable MagnetisMM-3 trial results in patients with relapsed or refractory multiple myeloma
Subscribe To Our Newsletter & Stay Updated
